KZR-616
( DrugBank: - / KEGG DRUG: - )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
| 50 | Dermatomyositis | 5 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 61 | Autoimmune hemolytic anemia | 1 |
| 63 | Idiopathic thrombocytopenic purpura | 1 |
49. Systemic lupus erythematosus
Clinical trials : 1,414 / Drugs : 1,077 - (DrugBank : 181) / Drug target genes : 130 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
50. Dermatomyositis
Clinical trials : 264 / Drugs : 298 - (DrugBank : 66) / Drug target genes : 71 - Drug target pathways : 173
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
61. Autoimmune hemolytic anemia
Clinical trials : 218 / Drugs : 186 - (DrugBank : 42) / Drug target genes : 27 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
63. Idiopathic thrombocytopenic purpura
Clinical trials : 868 / Drugs : 544 - (DrugBank : 96) / Drug target genes : 82 - Drug target pathways : 195
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
